2Fukuoka M,Yano S,Giaccone G, et al. Multi--institutional ran domized phase II trial of gefitinib for previously treated patients with advanced non small cell lung cancer[J]. J Clin Oncol,2003, 22(12):2237- 2246.
3Mendelsohn J, Baselga J. status of epidermal growth factor receptor antagonists in the biology and treatment of cancer[J]. J Clin Oncol,2003,21:2787-2799.
4Tam I Y S, Chung L P, Suen W S,et al. Distinct epidermal growth factor receptor and KRAS mutation patterns in non-small cell lung cancer patients with different tobacco exposure and clinicopathologic features[J]. ClinCancerRes,2006,12(5):1647--1653.
5Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-- small-- cell lung cancer: Results from a randomised, placebocontrolled, multieentre study (iressa survival evaluation in lung cancer) [J]. Lancet,2005,366(9496):1527- 1537.
6Lam D C, Girard L, Ramirez R, et al. Expression of nicotinic acetyleholine receptor subunit genes in non-- small -- cell lung cancer reveals differences between smokers and nonsmokers[J]. Cancer Res,2007,67(10) :4638--4647.
7Paez J G, Janne P A, Lee J C, et al. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy[J]. Science,2004,304(5676) : 1497-- 1500.
8Lorusso P M, Herbst R S, Rischin D,et al. Improvements in quality of life and disease--related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinases inhibitor ZD1839 in non small cell lung cancer and other solid tumor[J]. Clin Cancer Res, 2003,9 (6) : 2040-- 2048.
